Cargando…

Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia

OBJECTIVES: Different biomarkers such as C-reactive protein (CRP), serum ferritin and D-dimer are used in prognostic assessment of patients with COVID-19 pneumonia. Presepsin (PSP) is a soluble CD14 subtype that has recently been proposed as a novel biomarker in patients with sepsis. The aim of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Assal, Hebatallah Hany, Abdelrahman, Safaa Mohamed, Abdelbasset, Maha AlyAlden, Abdelaziz, Mai, Sabry, Irene Mohamed, Shaban, Marwa Moawad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893933/
https://www.ncbi.nlm.nih.gov/pubmed/35248717
http://dx.doi.org/10.1016/j.ijid.2022.02.054
_version_ 1784662524173484032
author Assal, Hebatallah Hany
Abdelrahman, Safaa Mohamed
Abdelbasset, Maha AlyAlden
Abdelaziz, Mai
Sabry, Irene Mohamed
Shaban, Marwa Moawad
author_facet Assal, Hebatallah Hany
Abdelrahman, Safaa Mohamed
Abdelbasset, Maha AlyAlden
Abdelaziz, Mai
Sabry, Irene Mohamed
Shaban, Marwa Moawad
author_sort Assal, Hebatallah Hany
collection PubMed
description OBJECTIVES: Different biomarkers such as C-reactive protein (CRP), serum ferritin and D-dimer are used in prognostic assessment of patients with COVID-19 pneumonia. Presepsin (PSP) is a soluble CD14 subtype that has recently been proposed as a novel biomarker in patients with sepsis. The aim of the current study was to detect the relation of PSP to the outcome of COVID-19 as well as its relation to other inflammatory biomarkers. METHODS: This multicenter retrospective observational study was conducted in Saudi Arabia and Misr International Hospital, Egypt, from January 2021 to May 2021. Hospitalised patients who had positive throat swab of SARS-CoV-2 and radiological evidence of viral pneumonia (moderate and severe forms) were included in the study. Demographics and clinical features, as well as laboratory parameters, including serum ferritin, CRP, D-dimer and PSP, of enrolled patients were retrospectively collected. Pneumonia severity index (PSI) was used to evaluate the severity of pneumonia. RESULTS: A total of 202 hospitalised patients who were diagnosed with COVID-19 pneumonia and tested positive for SARS-CoV-2 RNA were enrolled in our study. Of 202 hospitalised patients, 67 (33.17%) required intensive care unit (ICU) admission. A total of 176 (87.1%) patients survived and were discharged, whereas 26 (12.9%) patients did not survive. PSP level was found to be significantly elevated in nonsurvivor versus survivor group (median [IQR] 978.5 [755.8–1400] vs 516.5 [343.3–720], P<0.001) as well as in ICU versus non-ICU patients (median [IQR] 800 [631–1200] and 446 [320–626], respectively) (P<0.001). Elevated levels were also found to be associated with increased length of hospital stay. Levels above 775 pg/mL were found to be associated with in-hospital mortality (specificity 80%, sensitivity 73%). CONCLUSION: Elevated PSP levels indicated poor outcomes in hospitalised patients with COVID-19 pneumonia and were associated with in-hospital mortality.
format Online
Article
Text
id pubmed-8893933
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
record_format MEDLINE/PubMed
spelling pubmed-88939332022-03-04 Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia Assal, Hebatallah Hany Abdelrahman, Safaa Mohamed Abdelbasset, Maha AlyAlden Abdelaziz, Mai Sabry, Irene Mohamed Shaban, Marwa Moawad Int J Infect Dis Article OBJECTIVES: Different biomarkers such as C-reactive protein (CRP), serum ferritin and D-dimer are used in prognostic assessment of patients with COVID-19 pneumonia. Presepsin (PSP) is a soluble CD14 subtype that has recently been proposed as a novel biomarker in patients with sepsis. The aim of the current study was to detect the relation of PSP to the outcome of COVID-19 as well as its relation to other inflammatory biomarkers. METHODS: This multicenter retrospective observational study was conducted in Saudi Arabia and Misr International Hospital, Egypt, from January 2021 to May 2021. Hospitalised patients who had positive throat swab of SARS-CoV-2 and radiological evidence of viral pneumonia (moderate and severe forms) were included in the study. Demographics and clinical features, as well as laboratory parameters, including serum ferritin, CRP, D-dimer and PSP, of enrolled patients were retrospectively collected. Pneumonia severity index (PSI) was used to evaluate the severity of pneumonia. RESULTS: A total of 202 hospitalised patients who were diagnosed with COVID-19 pneumonia and tested positive for SARS-CoV-2 RNA were enrolled in our study. Of 202 hospitalised patients, 67 (33.17%) required intensive care unit (ICU) admission. A total of 176 (87.1%) patients survived and were discharged, whereas 26 (12.9%) patients did not survive. PSP level was found to be significantly elevated in nonsurvivor versus survivor group (median [IQR] 978.5 [755.8–1400] vs 516.5 [343.3–720], P<0.001) as well as in ICU versus non-ICU patients (median [IQR] 800 [631–1200] and 446 [320–626], respectively) (P<0.001). Elevated levels were also found to be associated with increased length of hospital stay. Levels above 775 pg/mL were found to be associated with in-hospital mortality (specificity 80%, sensitivity 73%). CONCLUSION: Elevated PSP levels indicated poor outcomes in hospitalised patients with COVID-19 pneumonia and were associated with in-hospital mortality. The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022-05 2022-03-03 /pmc/articles/PMC8893933/ /pubmed/35248717 http://dx.doi.org/10.1016/j.ijid.2022.02.054 Text en © 2022 The Author(s) Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Assal, Hebatallah Hany
Abdelrahman, Safaa Mohamed
Abdelbasset, Maha AlyAlden
Abdelaziz, Mai
Sabry, Irene Mohamed
Shaban, Marwa Moawad
Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia
title Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia
title_full Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia
title_fullStr Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia
title_full_unstemmed Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia
title_short Presepsin as a Novel Biomarker in predicting In‐hospital Mortality in Patients With COVID‐19 Pneumonia
title_sort presepsin as a novel biomarker in predicting in‐hospital mortality in patients with covid‐19 pneumonia
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8893933/
https://www.ncbi.nlm.nih.gov/pubmed/35248717
http://dx.doi.org/10.1016/j.ijid.2022.02.054
work_keys_str_mv AT assalhebatallahhany presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia
AT abdelrahmansafaamohamed presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia
AT abdelbassetmahaalyalden presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia
AT abdelazizmai presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia
AT sabryirenemohamed presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia
AT shabanmarwamoawad presepsinasanovelbiomarkerinpredictinginhospitalmortalityinpatientswithcovid19pneumonia